Literature DB >> 19574886

KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers.

Lizhi Zhang1, Thomas C Smyrk, Andre M Oliveira, Christine M Lohse, Shuya Zhang, Michele R Johnson, Ricardo V Lloyd.   

Abstract

Prediction of the biologic behavior of pancreatic endocrine tumor (PET) without local invasion or metastasis is often difficult. The 2004 World Health Organization (WHO) classification uses size, angioinvasion, mitotic activity, and Ki-67 index as prognostic criteria. Recently, cytokeratin 19 (CK19) was shown to be another prognostic marker, but the mechanism by which CK19 predicts prognosis is unknown. As CK19 is the first cytokeratin expressed in all epithelial cells in fetal pancreas, we sought to test expression of other markers of islet cell differentiation including KIT, Pdx-1, Pax4, and Pax6 in PET and correlation of these markers with clinical behavior. Clinical information and histology was reviewed in 97 PETs. All tumors were classified according to WHO criteria and a tumor, node, and metastases stage system. Immunohistochemistry was performed using antibodies to Ki-67, KIT, CK19, Pdx-1, Pax4, and Pax6. Associations of clinicopathologic and immunohistochemical features with prognosis were evaluated using Cox proportional hazards regression models. WHO and tumor, node, and metastases classifications, mitotic counts and Ki-67 labeling, infiltrative border, necrosis, perineural invasion, extrapancreatic extension, tumor size, and positive CK19 and KIT expression were significantly associated with death from disease in a univariate setting. In multivariate analysis, only WHO criteria and KIT expression were shown to be independent. An immunohistochemical classification system was derived from a combination of KIT and CK19 expression: low risk (KIT-/CK19-), intermediate risk (KIT-/CK19+), and high risk (KIT+/CK19+). Survival, metastases, and recurrence of PET were significantly different among the 3 groups. These results indicate that KIT is a new and independent prognostic marker for PETs. The classification system derived from KIT and CK19 was able to predict clinical behavior of PET.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19574886     DOI: 10.1097/PAS.0b013e3181ac675b

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  19 in total

1.  High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event.

Authors:  Thomas Knösel; Yuan Chen; Annelore Altendorf-Hofmann; Christine Danielczok; Martin Freesmeyer; Utz Settmacher; Christine Wurst; Stefan Schulz; Lin Lin Yang; Iver Petersen
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-08       Impact factor: 4.553

2.  An aptamer-based targeted delivery of miR-26a protects mice against chemotherapy toxicity while suppressing tumor growth.

Authors:  Toshihiko Tanno; Peng Zhang; Christopher A Lazarski; Yang Liu; Pan Zheng
Journal:  Blood Adv       Date:  2017-06-22

Review 3.  Surgical management of pancreatic neuroendocrine tumors.

Authors:  Wataru Kimura; Koji Tezuka; Ichiro Hirai
Journal:  Surg Today       Date:  2011-09-16       Impact factor: 2.549

Review 4.  [What is new in the pathology of pancreatic neuroendocrine tumors?].

Authors:  P Komminoth; A Perren
Journal:  Pathologe       Date:  2015-05       Impact factor: 1.011

Review 5.  Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms.

Authors:  Silvia Uccella; Stefano La Rosa; Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

6.  Comparison of PAX6 and PAX8 as immunohistochemical markers for pancreatic neuroendocrine tumors.

Authors:  Jin-Ping Lai; Richard B Mertens; James Mirocha; Jamie Koo; Mariza Venturina; Fai Chung; Allen B Mendez; Melissa Kahn; Deepti Dhall
Journal:  Endocr Pathol       Date:  2015-03       Impact factor: 3.943

7.  Comparison of Three Ki-67 Index Quantification Methods and Clinical Significance in Pancreatic Neuroendocrine Tumors.

Authors:  Trynda N Kroneman; Jesse S Voss; Christine M Lohse; Tsung-Teh Wu; Thomas C Smyrk; Lizhi Zhang
Journal:  Endocr Pathol       Date:  2015-09       Impact factor: 3.943

8.  Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival.

Authors:  Joo Young Kim; Sang Hwa Lee; Soyeon An; Sung Joo Kim; You-Na Sung; Ki-Byung Song; Dae Wook Hwang; Song Cheol Kim; Seung-Mo Hong
Journal:  Virchows Arch       Date:  2018-04-18       Impact factor: 4.064

Review 9.  Neuroendocrine tumors of the pancreas: current concepts and controversies.

Authors:  Michelle D Reid; Serdar Balci; Burcu Saka; N Volkan Adsay
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

10.  Expression of CK19 and KIT in resectable pancreatic neuroendocrine tumors.

Authors:  Xu Han; Jing Zhao; Yuan Ji; Xuefeng Xu; Wenhui Lou
Journal:  Tumour Biol       Date:  2013-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.